Y-Intercept (HK)’s FibroBiologics FBLG Stock Holding History

Y-Intercept (HK)’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-2,977	Closed	-$37K	–	2126
2025 Q2	$37K	Buy	+2,977	New	+$53.7K	﹤0.01%	1572

Other funds holding FBLG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

YAG

Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

CFP

Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Y-Intercept (HK)'s FBLG Position: Q3 2025 in Review

Y-Intercept (HK) sold out of FibroBiologics (FBLG) in Q3 2025, closing a stake of 2,977 shares — an estimated $37K sold.

Y-Intercept (HK) first reported a position in FBLG in Q2 2025 and held it in 1 quarter. The position peaked at $37K in Q2 2025. 52 funds tracked by Wall St. Rank hold FBLG as of Q3 2025.

Y-Intercept (HK) reported no remaining FibroBiologics position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 2,977 FibroBiologics shares in Q3 2025, an estimated $37K.
Y-Intercept (HK) first reported a position in FibroBiologics in Q2 2025 and held it in 1 quarter.
Y-Intercept (HK)'s FibroBiologics position peaked at $37K in Q2 2025.
52 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.